On December 18, 2020 the U.S. Food and Drug Administration (FDA) announced they have “issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older.” The FDA stated the “vaccine was 94.1% effective in preventing COVID-19 disease among these clinical trial participants with 11 cases of COVID-19 in the vaccine group and 185 in the placebo group.”
This comes the day after the December 17, 2020 VRBPAC meeting where they discussed the EUA of the Moderna COVID-19 Vaccine “for the prevention of COVID-19 in individuals 18 years and older.”
This EUA is granted 4 days after the first Pfizer-BioNTech vaccines was administered in the US and 10 days before the WHO declares the virus endemic the vaccines likely not to stop transmission!